3-cyclopentylprop-2-en-1-ol | 152972-34-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-cyclopentylprop-2-en-1-ol
• CAS: 152972-34-4
• 化学式: C₈H₁₄O
• 分子量: 126.199
• InChiKey: FYOMDMAJOTWCGR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-cyclopentylprop-2-en-1-ol 在 叔丁基过氧化氢 、 sodium hypochlorite 、 sodium dihydrogenphosphate 、 2-甲基-2-丁烯 、 D-(-)-酒石酸二乙酯 、 20 % Pd(OH)2/C 、 titanium(IV) isopropoxide 、 氢气 、 三氧化硫吡啶 、 二甲基亚砜 、 三乙胺 、 sodium hydroxide 作用下， 以 甲醇 、 正辛烷 、 二氯甲烷 、 水 、 乙腈 为溶剂， 反应 15.0h， 生成 (2R,3R)-2-(t-butoxycarbonylamino)-3-cyclopentyl-3-hydroxypropanoic acid
  参考文献：
  名称：

  Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: A highly potent orally available CCR5 selective antagonist

  摘要：

  Based on the original spirodiketopiperazine design framework, further optimization of an orally available CCR5 antagonist was undertaken. Structural hybridization of the hydroxylated analog 4 derived from one of the oxidative metabolites and the new orally available non-hydroxylated benzoic acid analog 5 resulted in another potent orally available CCR5 antagonist 6a as a clinical candidate. Full details of a structure-activity relationship (SAR) study and ADME properties are presented. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2011.05.022
• 作为产物：
  描述：

  methyl 3-cyclopentylacrylate 在 二异丁基氢化铝 作用下， 以 二氯甲烷 为溶剂， 生成 3-cyclopentylprop-2-en-1-ol
  参考文献：
  名称：

  N-苄氧基丙烯酰胺作为有机催化的 Domino aza-Michael/Morita-Baylis-Hillman 序列中的双亲核试剂

  摘要：

  我们在此描述了容易获得的丙烯酰胺和α,β-不饱和羰基之间的立体选择性有机催化的氮杂-迈克尔/森田-贝利斯-希尔曼多米诺骨牌反应。这种新颖的、PPh 3促进的原子经济一锅法具有中等至良好的产率和良好的立体选择性，导致具有环外烯键的各种取代的哌啶-2-酮，这被证明是进一步化学多样化的优异锚定。

  DOI：

  10.1021/acs.orglett.4c00295

文献信息

• Ir(I)-Catalyzed Enantioselective Decarboxylative Allylic Etherification: A General Method for the Asymmetric Synthesis of Aryl Allyl Ethers
  作者：Dongeun Kim、Srinivasa Reddy、Om V. Singh、Jae Seung Lee、Suk Bin Kong、Hyunsoo Han

  DOI：10.1021/ol3033237

  日期：2013.2.1

  Ir(I)-catalyzed enantioselective decarboxylative allylic etherification of aryl allyl carbonates provides aryl allyl ethers. Key to the generality and high stereoselection of the reaction is the use of the intramolecular decarboxylative allylation process and [Ir(dbcot)Cl]2 as an Ir(I) source. Ir(I)-catalyzed diastereoselective decarboxylative allylic etherification, combined with asymmetric aldehyde

  Ir（I）催化的芳基碳酸烯丙酯的对映选择性脱羧烯丙基醚化反应提供了芳基烯丙基醚。反应的一般性和高立体选择的关键是使用分子内脱羧烯丙基化过程和[Ir（dbcot）Cl] 2作为Ir（I）来源。Ir（I）催化的非对映选择性脱羧烯丙基醚化反应，与不对称醛的crotylation和交叉复分解相结合，可以提供具有高非对映选择性的单保护的2-甲基-1,3-二醇（从简单的醛开始）。
• Discovery of Potent Benzofuran-Derived Diapophytoene Desaturase (CrtN) Inhibitors with Enhanced Oral Bioavailability for the Treatment of Methicillin-Resistant <i>Staphylococcus aureus</i> (MRSA) Infections
  作者：Youxin Wang、Feifei Chen、Hongxia Di、Yong Xu、Qiang Xiao、Xuehai Wang、Hanwen Wei、Yanli Lu、Lingling Zhang、Jin Zhu、Chunquan Sheng、Lefu Lan、Jian Li

  DOI：10.1021/acs.jmedchem.5b01984

  日期：2016.4.14

  Blocking the staphyloxanthin biosynthesis process has emerged as a new promising antivirulence strategy. Previously, we first revealed that CrtN is a druggable target against infections caused by pigmented Staphylococcus aureus (S. aureus) and that naftifine was an effective CrtN inhibitor. Here, we identify a new type of benzofuran-derived CrtN inhibitor with submicromolar IC50 values that is based on the naftifine scaffold. The most potent analog, 5m, inhibits the pigment production of S. aureus Newman and three MRSA strains, with IC50 values of 0.38-5.45 nM, without any impact on the survival of four strains (up to 200 mu M). Notably, compound 5m (1 mu M) could significantly sensitize four strains to immune clearance and could effectively attenuate the virulence of three strains in vivo. Moreover, 5m was determined to be a weak antifungal reagent (MIC > 16 mu g/mL). Combined with good oral bioavailability (F = 42.2%) and excellent safety profiles, these data demonstrate that 5m may be a good candidate for the treatment of MRSA infections.